Beyond Instrument Placement: Incentive Compensation Strategies for Clinical Diagnostics
Same Instrument, Different Accounts. Two Outcomes, and Your Model Doesn’t Know Why.
Two reps can sell the same equipment and get very different results. Placement is easy to track and reward. But adoption, installed-base retention, and a consistent account experience determines whether a territory performs. Most plans, and the campaigns built to support them, still treat every placement the same: a new logo is the same as an expansion sale, a mature account is the same as whitespace, and a displaced competitor is the same as one simply matched. This Axtria white paper explains how to fix that.
WHO THIS IS FOR
Sales Operations leaders responsible for quota, territory design, and crediting mechanics, and Brand and Marketing Operations leaders responsible for the campaigns, messaging, and account-level positioning that support the field. Clinical and R&D leaders will also find this useful, since they use the instruments for clinical studies.
WHAT'S INSIDE
- New logo versus expansion crediting, and what that split means for how each is targeted and messaged
- Segmenting territories by installed-base density, so whitespace and mature accounts get different quota mix and different campaign support
- Competitive displacement bounties sized to throughput, and the conversion messaging built to back them
- Multi-channel ownership models for large reference labs and health systems, with a shared scorecard that keeps capital, reagent, service, and marketing pointed at one account outcome
- The data infrastructure — Laboratory Information System, Customer Relationship Management, and Enterprise Resource Planning — that both crediting and campaign targeting depend on
Neither function can fix this alone. A quota rebuilt around installed-base density needs campaigns segmented the same way, and campaigns segmented that way need a quota structure that rewards reps for working them.
If sales territories are built around installed-base density but marketing campaigns target accounts on different criteria, which one tells the rep what to prioritize?
Want to align your territory model and campaign segmentation to the same framework? Request a working session with Axtria's Commercial Excellence team.
FAQs
A clinical diagnostics incentive compensation strategy aligns sales crediting and commission structures with the full revenue lifecycle—instrument placement, reagent pull-through, and service retention—rather than rewarding only the capital equipment placement event. Axtria’s white paper outlines how life sciences companies can redesign incentive plans to reflect the razor/razor blade economics that drive long-term account profitability.
Most incentive compensation plans credit the field at instrument placement, disconnecting pay from the consumable and reagent revenue that drives margin over the account’s lifetime. This placement-first design incentivizes reps to move on after installation rather than manage utilization and installed-base longevity.
Sales compensation plan design for diagnostics should shift credit weight away from the placement event and toward verified installation milestones and ongoing reagent or consumable volume, ensuring commission expense aligns with the revenue it is paid against. Axtria’s clinical diagnostics sales strategy framework addresses how to balance capital equipment crediting with consumable attach rates across multi-channel, team-selling accounts.
Reagent rental structures and equipment discounts tied to consumable volume commitments can increase Anti-Kickback Statute and Stark Law exposure, so incentive plan design should include clear regulatory guardrails. Life sciences companies must ensure that sales crediting and discount approval processes do not create improper inducements under federal healthcare fraud and abuse laws.
You can build installed base management accountability into incentive compensation by assigning ongoing reagent revenue targets and service-retention metrics to the reps or account teams responsible for each placement. This approach to life sciences incentive plan design reduces reagent leakage to secondary-market channels and ties compensation expense directly to each account’s durable profitability.
Recommended insights
Case Study
White Paper
White Paper